$TEVA reported Q4 results:New debt to ebitda on a forward looking basis Forecast ebitda 4.7-5.0 billion for 2018Debt 32.5 as of December 31 2017Debt to ebitda on a front looking basis now 6.5-7.0$VRX and $TEVA both have the same debt to EBITDATEVA: $TEVA, Teva Pharmaceutical Industries Limited / H1 Valeant: $BHC, Bausch Health Companies Inc. / H1 Both TEVA and VRX are buys. Agree or disagree?